ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Counter-Point: George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer

July 11, 2014

AACR’s First Special Conference Scheduled for Oct. 23-27 at Cape Cod

July 22, 1988

FDA Advisors Okay NCI Toxicology Proposals, Write New Clinical Guidelines, Approve AIN DA

October 19, 1979

National Comprehensive Center Network, Quintiles Oncology, To Collaborate On Trials

March 5, 1999

Recombinant Protein C Cuts Risk Of Sepsis Death

February 22, 2002

New CCOP RFA To Encourage Cancer Control Research; Larger But Fewer Awards Are Likely

May 9, 1986